Pacific Biosciences Of California (PACB) EBT Margin Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) EBT Margin Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -419.00 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 110.00 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 458.00 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 507.00 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -287.00 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 772.00 |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 233.00 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -464.00 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn | 112,586.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 112,586.00 |
| Dec 31, 2025 | -9,682.00 |
| Sep 30, 2025 | 5,408.00 |
| Jun 30, 2025 | 37,591.00 |
| Mar 31, 2025 | -94,619.00 |
| Dec 31, 2024 | 14,863.00 |
| Sep 30, 2024 | -1,264.00 |
| Jun 30, 2024 | -33,448.00 |
| Mar 31, 2024 | 2,482.00 |
| Dec 31, 2023 | 16,672.00 |
| Sep 30, 2023 | 9,892.00 |
| Jun 30, 2023 | 5,451.00 |
| Mar 31, 2023 | 1,942.00 |
| Dec 31, 2022 | -11,928.00 |
| Jun 30, 2022 | 8,680.00 |
| Mar 31, 2022 | -11,451.00 |
| Dec 31, 2021 | -46,536.00 |
| Jun 30, 2021 | 18,723.00 |
| Mar 31, 2021 | 8,450.00 |
| Dec 31, 2020 | 34,565.00 |